ClinicalTrials.gg
RecruitingNCT07121413Updated Feb 11, 2026

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of SV001 and Placebo in Idiopathic Pulmonary Fibrosis(IPF), sponsored by Shanghai Synvida Biotechnology Co.,Ltd.. Recruiting at 12 sites in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Shanghai Synvida Biotechnology Co.,Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
39th of 60
48 · median 83
Started
2025
with 9 others
Phase 2
21 of 67
7 open now
Primary completion
2026-12
later than 7 of 28 live
Registered
54th of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 39th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 21 in phase 2, reaches primary completion later than 7 of the 28 other live ones, and was the 54th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis(IPF)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with a confirmed diagnosis of IPF and pulmonary function meeting the protocol-specified criteria;
  2. Subjects must agree to use highly effective during the study and for 6 months after the last administration of the study drug;
  3. Subjucts must be able to understand the study, voluntarily provide written , and be willing and able to comply with all study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of drug or other allergies, or those judged by the investigator to be potentially allergic to the study drugs;
  2. Presence of any other pulmonary diseases besides IPF at screening;
  3. Any known to performing pulmonary function tests at screening;
  4. Respiratory or systemic infections requiring anti-infective therapy within 1 month prior to randomization;
  5. Acute exacerbation of IPF within 4 months prior to randomization;
  6. Use of any medication known to cause or worsen pulmonary fibrosis, as assessed by the investigator, within 3 months prior to screening;
  7. History of smoking within 3 months prior to screening, or unwillingness to quit smoking throughout the study period;
  8. Presence of clinically significant cardiovascular, cerebrovascular, hematological, neurological, psychiatric, or metabolic disease at screening, or plans for major surgery during the study period;
  9. Presence of specified abnormal laboratory test results at screening;
  10. Evidence of renal impairment or end-stage renal disease requiring dialysis at screening;
  11. Active hepatitis virus infection; history of acquired or congenital immunodeficiency disease;
  12. History of within 5 years prior to screening;
  13. Difficulty with venipuncture or a history of needle phobia or blood phobia;
  14. Positive pregnancy tests or currently lactating at screening;
  15. Participation in another clinical trial and receipt of other drugs within 3 months prior to randomization;
  16. Any other condition that the investigator consider unsuitable for participation in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    SV001

    Drug: SV001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSV001

    SV001 : Multiple-dose

  • DrugPlacebo

    Placebo : Multiple-dose

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Adverse event type, incidence, duration

    Time frame: Approximately 1 years

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  2. Peak time(Tmax)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  3. Area under the plasma concentration versus time curve (AUC)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  4. half-life(T1/2)

    PK (Pharmacokinetics)

    Time frame: Approximately 1 years

  5. Immunogenicity

    ADA(Anti-drug antibody)

    Time frame: Approximately 1 years

07

Study locations

12 of 12 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 13 months is below that.

Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 13, 2025
StartActual
Nov 4, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07121413
Lead sponsor
Shanghai Synvida Biotechnology Co.,Ltd.
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Nov 4, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 11, 2026

Study contacts

Jinfu Xu
Contact
hdyyll@126.com
86-21-62483180

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion